Carla Rovirosa Martí
Técnico/a de laboratorio
Grupo de investigación
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes